GET DAILY SIGNALSBruker (BRKR) Delivers +24.4% Non-GAAP EPS Growth in Q3 2026 on Margin Expansion
Key Takeaways
- Bruker reported third quarter 2026 revenue of $874.0 million, up 1.6% year over year, with organic growth of 0.7%.
- Non-GAAP (adjusted) diluted earnings per share (EPS) reached $0.56, up 24.4% from $0.45 a year earlier and well above the roughly $0.42 consensus estimate.
- Non-GAAP operating margin expanded 400 basis points to 16.3%, driven by cost savings and favorable product mix.
- GAAP results were weighed down by a $174.5 million non-cash goodwill impairment tied to Bruker Spatial Biology, producing a GAAP diluted loss of $0.81 per share.
- Free cash flow swung to $96.7 million from negative $54.1 million a year ago, and the company reaffirmed its full-year 2026 non-GAAP EPS guidance of $2.10 to $2.15.
- For additional context on the company, you can review its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Interested traders and investors can also explore Trending AI Robots for additional market signals and ideas.
Earnings Context and Why It Matters
BRKR is a leading maker of high-performance scientific instruments and analytical and diagnostic solutions used across life science research, diagnostics, and semiconductor metrology. Its third quarter 2026 report, released on November 4, 2026, matters because it shows whether the company can convert a still-modest top line into meaningfully higher profitability. After several quarters of soft instrument demand, investors were watching closely for evidence that order momentum and cost discipline could support a broader recovery. The results landed amid a fifth consecutive quarter of book-to-bill above one in the Bruker Scientific Instruments segment, signaling that improving demand and disciplined execution may be positioning the business for accelerating growth into fiscal 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
BRKR posted third quarter 2026 revenue of $874.0 million, a 1.6% increase from $860.5 million in the prior-year period. Organic revenue rose 0.7%, acquisitions added 1.7%, and foreign currency translation was a 0.8% headwind. The core Bruker Scientific Instruments (BSI) segment generated $793.9 million, up 0.8% but down 0.4% organically, while Bruker Energy & Supercon Technologies (BEST) revenue climbed 11.2% to $82.1 million.
Profitability was the standout. Non-GAAP diluted EPS came in at $0.56, up 24.4% from $0.45 a year earlier and comfortably ahead of the consensus estimate of about $0.42. Non-GAAP operating margin expanded to 16.3% from 12.3%, helped by roughly $140 million in annualized cost-out actions and favorable mix. Non-GAAP gross margin improved 120 basis points to 51.3%.
On a GAAP basis, the quarter included a $174.5 million non-cash goodwill impairment related to Bruker Spatial Biology, contributing to a GAAP diluted loss of $0.81 per share versus a $0.41 loss a year earlier. Management reaffirmed full-year 2026 non-GAAP EPS guidance of $2.10 to $2.15 and narrowed reported revenue expectations to $3.52 to $3.56 billion, reflecting currency headwinds.
Market Reaction and Investor Sentiment
Investors responded favorably to the margin-led beat. BRKR shares rose sharply in the session following the release, climbing roughly 8% to around $61 per share as the market focused on the stronger-than-expected non-GAAP EPS and the improved order book rather than the headline GAAP loss. The $174.5 million spatial biology impairment, the second consecutive write-down in that unit, was largely treated as a non-cash item, though it kept some caution in the air. Sentiment was further supported by management's commentary pointing to a fifth straight quarter of BSI book-to-bill above one, double-digit growth in U.S. academic and government bookings, and more than 20% growth in China bookings year to date. From what I see, the order trends stand out as a positive signal worth monitoring.
Forward Outlook and Key Factors to Monitor
BRKR's reaffirmed full-year 2026 guidance, including 1% to 2% organic revenue growth and non-GAAP EPS of $2.10 to $2.15, frames a fourth quarter that will hinge on converting a growing backlog into revenue. Management indicated the fourth-quarter revenue ramp is now almost entirely covered by backlog, with a limited amount of site-readiness risk remaining.
Looking further ahead, investors will want to track whether semiconductor metrology orders, which grew more than 30% year to date and are tied to the artificial intelligence build-out, begin converting into revenue during fiscal 2027 and 2028. The recovery in U.S. academic and government research funding, the first year-over-year bookings growth since the 2025 National Institutes of Health funding disruption, is another key signal to monitor. Cost trends and margins also remain central. Continued progress on the $140 million cost-out program, combined with product mix, will determine whether Bruker can sustain double-digit EPS growth. Currency movements and the effective tax rate, which rose to 28.4% in the quarter, are additional variables worth watching. No price predictions are warranted, but the balance between a recovering order book and still-modest organic revenue growth will likely define the narrative into 2027. I’m watching this closely as the backlog conversion unfolds.
Using Tickeron’s AI Screener for Deeper Analysis
In my regular research workflow, Tickeron’s AI Screener serves as a practical way to scan for stocks with similar technical patterns, fundamentals, and AI-driven signals. It helps filter thousands of names efficiently by industry, market cap, volatility, and performance metrics, which can surface relevant comparisons or ideas during earnings season without relying solely on manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BRKR turns positive, indicating new upward trend
BRKR saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 74 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +6.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 198 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for BRKR turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 33 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
BRKR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BRKR crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
BRKR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.615) is normal, around the industry mean (4.170). P/E Ratio (-80.714) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.253). Dividend Yield (0.004) settles around the average of (0.010) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of analytical and medical instruments
Industry MedicalNursingServices
Advertisement